Installations at National Taiwan University and National Cheng Kung University expand Nuclera’s global footprint with first commercial sales in Asia
System strengthens Taiwan’s capabilities in protein drug discovery research
Cambridge, UK, and Boston MA, USA, 07 January 2026: Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, today announced that it has completed the first installations of eProtein Discovery in Asia, with systems now operational at the Department of…
Change in role from Chief Data Officer reflects Qureight’s continued growth and commercial success in delivering customers’ clinical studies
Cambridge, UK, 07 January 2026 – Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials, today announced the appointment of Dr Steven Bishop as Chief Medical Officer (CMO). Previously Chief Data Officer, Steven’s new role reflects changes in company structure, in response to continued growth and commercial…
Welcome to 2026 with One Nucleus
By Tony Jones, CEO, One Nucleus
It feels great returning to work when it is striking that many people are feeling more optimistic about the Life Science sector investment outlook at present than at this time last year, or indeed for most of 2025. Deal flow in terms of private investment, M&A and follow-on financings appeared to be on the rise through late 2025.
It may be too early to feel confident the bear market is over, investment will flow and growth will return consistently, but the signs look very encouraging. Heading off to San Francisco at the…
LONDON, UK – January 7, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Alethio Therapeutics – formerly known as Alethiomics – and is pleased to announce the placement of Dr. Rohit Batta as Chief Executive Officer.Alethio Therapeutics is a biotech company advancing therapies designed to help people with Myeloproliferative Neoplasms (MPNs) live longer, healthier, and more fulfilling lives. Backed by deep scientific and clinical expertise, the Company is…
Ikarovec to advance pipeline with exclusive worldwide option to VectorBuilder’s Intravitreal Capsid Technology
Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease
NORWICH, UK & CHICAGO, US, January 6 2026 – Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a global leader in gene delivery technologies, have entered into an exclusive worldwide option agreement for VectorBuilder’s novel AAV capsid…
We’re kicking off the new year with a full calendar of courses covering a broad mix of skills. Whether you’re looking to sharpen existing expertise or explore something new, there’s something for everyone to discover and learn throughout the year.
27 January 2026 | The Safe Use and Management of Laboratory Gases Register Here...
This one-day workshop empowers lab, stores, and facilities managers with practical tools, audit checklists, and real-world case studies to ensure compliant and safe handling of gases under pressure. Perfect for anyone responsible for lab operations and…
Calling all academics, clinicians, entrepreneurs, start-ups, and industry partners who want to turn early-stage medical technologies into safe, sustainable, clinically ready devices.The Institute for Biomedical Innovation (IBI) is a new major investment by the University of Cambridge. Based in the Department of Engineering, the IBI aims to turn early-stage medical technologies into safe, sustainable, clinically ready devices. It will combine a state-of-the-art prototyping facility equipped for microfabrication, device assembly, and biological testing, with an innovation support programme that…
NEW BioBiz Buzz EPISODE ALERT: “From the Horse’s Mouth — Inside Pharma’s Most Volatile Year”What a year it’s been. Pharma’s first $1 trillion company. A $400 billion collapse. Mass layoffs, geopolitical upheaval, AI valuations soaring, and a regulatory reset that changes everything for rare disease developers.In this unmissable episode of #BioBizBuzz, host Jo Shorthouse sits down with Mike Ward, Clarivate’s Global Head of Life Sciences & Healthcare Thought Leadership, fresh from his “Winners & Losers” keynote at One Nucleus’s 25th Genesis conference in London.Together they unpack…
Tony JonesCEO, One Nucleus
It has been a very tough year for the sector and most in it for certain, and I and the One Nucleus team would like to thank all of our sponsors, members and network for your unwavering support as we have sought to enable your respective 2025 journeys.As the office and laboratory lights start to dim for the festive break, as the data points and sentiment appear to be leaving towards an optimistic mood for 2026 in many quarters, it is a pleasure to write and highlight some key dates for your diaries where we will again be looking to enable our network to be…
The industry is increasingly focused on speeding up antibody validation and biopharmaceutical research and development. Efficient execution of these processes, along with effective management of regulatory milestones, has become a central concern across the field. Creative Biolabs has recently officially launched a full-process service portfolio covering "from discovery to production", providing biopharmaceutical companies with faster, more stable, and more scalable technical channels."We have observed that there is an increasing number of projects with a gap between the early-stage…